Oramed Pharmaceuticals Inc. (ORMP)
NCM · Healthcare · Biotechnology
$3.87
+1.84%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$158.4M
Shares Outstanding
40.9M
Exchange
NCM
Currency
USD
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.5M | -2.4M | -5.7M | -3.7M |
| Net Income | 13.3M | 48.4M | 10.0M | 38.3M |
| Diluted EPS | $0.31 | $1.13 | $nan | $0.91 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 2.7M | 1.3M | 0.00 | 2.0M |
| Gross Profit | 0.00 | 13K | ||
| Operating Income | -40.6M | -15.8M | -12.8M | -15.1M |
| Net Income | -36.6M | 5.5M | -19.1M | 64.0M |
| Diluted EPS | $-0.94 | $0.14 | $-0.48 | $1.50 |